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Abstract
Background: Prostate cancer is the fourth commonest cancer in the UK, and the incidence is
rising. The reference standard for diagnosing this condition is prostate biopsy, an invasive
procedure.
This study systematically reviews recent literature on tPSA accuracy. The time period was
restricted to ensure that the estimates referred to contemporary tPSA tests and prostate cancer
reference standards. The focus of this review was restricted to European populations as tPSA levels
are known to vary by population group.
Methods: Medline was searched (from 01/1998 to 01/2008) and Embase (from 01/1998 to 01/
2008), which returned 3087 citations. These were assessed by 6 reviewers, who shortlisted 54 of
possible relevance. 2 reviewers assessed each using the following inclusion criteria: data collection
between 1998-2008; tPSA measurements for all participants; histological confirmation of the
diagnosis; samples from a European population and sufficient data to calculate 2 × 2 tables. The final
set of 10 included studies represented 5373 participants. Quality of the included studies was
assessed in duplicate using criteria suggested by the Cochrane Collaboration. Review Manager 5.0
software was used to analyse the data, including plotting a series of summary receiver operator
curve spaces (SROC).
Results: tPSA sensitivities ranged from 0.78 to 1.00 and specificities from 0.06 to 0.66. Positive
likelihood ratios ranged from 0.83 to 2.90 and negative likelihood ratios ranged from 0.00 to 3.75
Conclusion: tPSA has a role to play as one of several indicators for prostate biopsy along with
abnormal digital rectal examination and urinary symptoms. However, tPSA test has a high false
positive and significant false negative rate. It is important that clinicians understand these limitations.
Background
There were 28,886 newly diagnosed cases of prostate can-
cer in 2005 in England, comprising 24.1% of all cancers
in men in that year. It is the fourth commonest cancer in
the UK [1]. In 2005 9024 men died of prostate cancer,
mostly between the ages of 80-84 [2]. The incidence of
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2004 [3], to 301,500 in 2006 [4]. It remained the com-
monest cause of cancer in European men and the third
commonest cause of death. The incidence is rising, partly
due to our ageing population [5]. Total prostate specific
antigen (tPSA) testing has risen significantly from 1999 to
2002 [6]. It is therefore important that the validity of the
tPSA test be fully understood to ensure appropriate testing
and referral for further investigations.
However tPSA testing was not intended as a diagnostic
test, but for identifying individuals requiring further
investigation [7]. NICE currently recommend the Prostate
Cancer Risk Management Programme's age specific ranges
for tPSA cut off levels (Table 1). NICE describe the test as
moderately sensitive and specific [8]. However no evi-
dence is provided for this, despite claiming their judge-
ment is based on secondary research and selected primary
research. Patients with a tPSA higher than the given level
are recommended to undergo further investigation. How-
ever, there is great variation in clinical practice within the
UK [5], with some trusts using a single cut off value of 4
ng/mL and some using the age specific ranges as shown in
table 1.
tPSA is an inherent part of the prostate cancer diagnosis
pathway. This comprises of symptoms, digital rectal
examination (DRE), tPSA level and transurethral ultra-
sound guided biopsy (TRUS) (Figure 1). Although it is not
certain what the diagnostic pathway would be like in the
absence of tPSA, it seems likely that virtually all patients
with suspicious clinical findings would require biopsy.
In the past few years there has been substantial debate
regarding the role of tPSA as a diagnostic tool. There is a
large quantity of literature available on tPSA and a simple
search of the term PSA OR Prostate Specific Antigen in
PubMed gives 20,469 hits. Furthermore the introduction
of screening in the USA has brought discussion of whether
a similar screening programme should be introduced in
Europe. At the centre of this debate is the uncertainty of
the diagnostic accuracy of the tPSA test. The focus of this
review will be the diagnosis of prostate cancer in patients
presenting with symptoms. However other forms of PSA
testing such as PSA velocity, PSA density and free to total
PSA ratios are not assessed. This is a reflection of clinical
practice as they are of limited value and not included in
the European guidance [9].
In 1999 the World Health Organisation (WHO) estab-
lished a reference standard for total PSA measurement
[10]. Since then, differences have decreased between the
results of different assay methods [11]. Also, the Standard
for the Reporting of Diagnostic Accuracy Studies (STARD)
was formulated in September 2000, to improve the accu-
racy and completeness for reporting diagnostic accuracy
studies. Its aim is to encourage a more standardised and
transparent format for diagnostic test studies [12]. This
review upholds these standards.
Objectives
In this systematic review we aim to assess the sensitivity
and specificity of the PSA test in the diagnosis of prostate
cancer.
Methods
Criteria for considering studies for this review
Types of studies
Analytical studies assessing the accuracy of tPSA in pre-
dicting the diagnosis of prostate cancer. Only published
English-language studies, carried out and published
within the last 10 years (1998-2008) were considered for
inclusion.
Participants
Men participating in studies of prostate cancer diagnosis,
carried out in Europe. No age restrictions were used.
Table 1: Watson 2002
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Total prostate specific antigen testing. Only papers in
which a full range of tPSA from <4 ng/mL to >10 ng/mL
as this reflects the standard European practice.
Target conditions
Prostate cancer, irrespective of Gleason or TNM score.
Reference standards
Histological confirmation of prostate cancer either from a
biopsy or resected specimen.
Search methods for identification of studies
Electronic searches of MEDLINE and EMBASE were per-
formed.
Electronic searches
The following search strategy for MEDLINE was per-
formed via Pubmed in January 2008: ("Prostate-Specific
Antigen" [Mesh] AND "Prostatic Neoplasms" [Mesh])
AND ("Diagnostic Techniques and Procedures" [Mesh]
OR "Sensitivity and Specificity" [Mesh]) AND "diagnosis/
broad" [Filter] AND "english and humans" [Filter] AND
("last 10 years" [PDat])
The following search strategy was used for EMBASE via
OVID in January 2008:
1. exp prostate cancer/di
2. limit 1 to (human and english language and year =
1998-2008)
3. exp diagnostic techniques and procedures/
4. exp sensitivity and specificity/
5. 3 or 4
6. exp prostate specific antigen/
7. 2 and 5 and 6
Data collection and analysis
Selection of studies
A list of articles meeting the inclusion criteria based on
abstracts was complied. These studies and those of uncer-
tain relevance were retrieved in full text and split into
three groups based on date of publication. Two reviewers
independently evaluated each group of studies for inclu-
sion, with any discrepancies being discussed with a third
reviewer until a final set of relevant studies was agreed.
Data extraction and management
The following data was extracted from each study:
 Study citation
 Clinical setting (clinic or screening)
 Participants (number, age range)
 Study design
 Characteristics of tPSA test
 Reference standard
 Study results (i.e. specificity, sensitivity, 2 × 2 table)
The data was entered into Review Manager 5.0 software.
Assessment of methodological quality
The methodological quality for each paper was assessed
by 2 reviewers independently using the QUADAS [13] cri-
teria [see Additional file 1].
Statistical analysis and data synthesis
Sensitivity, specificity, true positives (TP), false positives
(FP), true negatives (TN) and false negatives (FN) were
taken directly from the source papers. If this was not pos-
sible, values were calculated from the data that was pro-
vided. Positive and negative likelihood ratios, diagnostic
odds ratios, and 95% confidence intervals were calcu-
lated. The data was displayed graphically on forest and
SROC plots. The SROC curve was fitted using the Litten-
berg-Moses method.
Investigations of heterogeneity
Heterogeneity between studies was assessed and subgroup
analyses were performed using study design as the main
variable.
Results
The search provided 3087 citations, 2580 from Medline
and 492 from EMBASE. 54 were short listed and 10 were
included. Studies excluded from the short list either did
not fully meet the inclusion criteria or did not contain the
appropriate data for our analysis. [see Additional file 2]
Included Studies
Participant numbers of included studies varied from 59 to
3171 with a mean of 537. The total patient population
was 5373. Seven studies had a prospective cohort design
and three were retrospective case control studies. For
detailed tables of study characteristics please see Addi-
tional file 3.
Unal 2000 and Espana 1998 included both European and
non-European centres. A consensus was reached that stud-
ies should be included if all hospitals listed as researchPage 3 of 9
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tion.
Espana 1998 performed two tPSA tests on each partici-
pant using the second for the main statistical analysis.
Only the first test data fit the criteria for this review, there-
fore this data was used.
Aragona 2005 involved 16,298 participants. However
only 3,171 underwent biopsy and hence only these
patients were included in our analysis.
Methodological quality of included studies
Figure 2 shows the overall quality of the 10 included stud-
ies. In particular, the explanation of withdrawals and
index blinding were poorly reported. It is also unclear
whether uninterpretable results were reported. These are
potentially important sources of bias.
A breakdown of the methodological quality can be found
in Figure 3. It can be seen that the Espana 1998 study had
low quality index blinding and withdrawal explanation.
The Aragona 2005 study had low quality reporting of
uninterpretable results; eight of the patients in this study
were lost without explanation. This is significant as this
study contributed the largest proportion of our total data.
The Unal 2000 study had low quality reporting of index
blinding. This is perhaps less significant as this study is the
smallest and blinding of the index test has a minimal
effect on the PSA test and its interpretation. However the
small size of this study has meant that findings, such as a
false negative rate of 0, need to be interpreted cautiously.
Statistical analysis
Table 2 displays core information collected from all
included studies. This data is graphically displayed in Fig-
ure 4. Sensitivities varied from 0.78 to 1.00 (range of
0.22) and specificities ranged from 0.06 to 0.66 (range of
0.60).
Positive and negative likelihood ratios and diagnostic
odds ratios (DORs) are displayed in Table 3. DORs are
displayed in a forest plot in Figure 5. Only 9 of the 10
studies were plotted as the confidence intervals (CIs) of
the odds ratio for the Unal 2000 study could not be calcu-
lated.
All studies have a DOR above 1 except Espana 1998 and
Wymenga 2000. Fischer 2005 has an odds ratio of 1.729
but the CI crosses 1. The remaining six studies all have
their odds ratios above 1 and CIs that do not include 1,
implying that the positive association of tPSA with pros-
tate cancer is not accounted for by chance alone in these
Methodological quality graph: review authors' judgments about each methodologic l quality item presented as per-centag s across all included studiesFig r  2
Methodological quality graph: review authors' judg-
ments about each methodological quality item pre-
sented as percentages across all included studies.
Methodological quality summary: review authors' judgments about each methodological quality item for each included studyFig r  3
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the other studies, which may be attributed to its large size.
Positive likelihood ratios (PLR) were above 1 for all stud-
ies except Espana 1998 and Wymenga 2000, indicating
that a raised tPSA is associated with prostate cancer. How-
ever all PLRs are below 10, the threshold generally
accepted for a useful test. The same eight studies have neg-
ative likelihood ratios (NLR) less than 1 indicating that a
low tPSA is correctly associated with not having the dis-
ease. However only one meets the accepted level of less
than 0.1.
The SROC curve [Figure 6] lies to the left of the diagonal
signifying that the tPSA test has value. The SROC analysis
was further developed by placing the studies into sub-
groups based up trial design. [Figure 7].
Subgroup analysis
To explore the heterogeneity, subgroups of cohort and
case control, and pre-1999 and post-1999 were created.
Summary receiver operating characteristic (SROC) curves
were plotted for each subgroup. Figure 7 shows greater test
accuracy in the case control subgroup, figure 8 shows test
accuracy was greater post-1999, most likely due to the
WHO guidelines instigated that year. Outlying studies;
Espana 1998, Wymenga 2000 and Unal 2000, can be
accounted for by either case-control design or pre-1999
assays.
Discussion
Overall tPSA seems to have significance as a diagnostic
tool. DORs ranged from 0.221 to 4.16. All but two studies
gave DORs greater than 1. The SROC curve [Figure 6] lies
to the left of the diagonal signifying that the PSA test has
value. Adequate levels of sensitivity appear to be achieved
at the expense of poor specificity, with consequently rela-
tively high numbers of false positive results.
Espana 1998 and Wymenga 2000 had DORs below 1.
This suggests that the PSA of more than 4 ng/ml is
inversely associated with prostate cancer. Potential
sources of bias for Espana 1998 are its age and poor expla-
nation of withdrawn participants. Its small size makes it
Table 2: True positives (TP), false positives (FP), true negatives (TN), false negatives (FN), sensitivity and specificity for all studies with 
95% confidence intervals.
Study Participants TP FP FN TN Sensitivity [CI] Specificity [CI]
Aragona 2005 3171 1073 1695 98 305 0.92 [0.90, 0.93] 0.15 [0.14, 0.17]
Beneduce 2007 101 42 31 8 20 0.84 [0.71, 0.93] 0.39 [0.26, 0.54]
Ciatto 2004 410 167 171 18 54 0.90 [0.85, 0.94] 0.24 [0.19, 0.30]
Espana 1998 170 53 96 15 6 0.78 [0.66, 0.87] 0.06 [0.02, 0.12]
Fischer 2005 178 61 76 13 28 0.82 [0.72, 0.90] 0.27 [0.19, 0.37]
Hofer 2000 184 67 81 7 33 0.91 [0.81, 0.96] 0.29 [0.21, 0.38]
McArdle 2004 171 93 52 10 16 0.90 [0.83, 0.95] 0.24 [0.14, 0.35]
Ryden 2007 361 180 146 8 27 0.96 [0.92, 0.98] 0.16 [0.11, 0.22]
Unal 2000 59 30 10 0 19 1.00 [0.88, 1.00] 0.66 [0.46, 0.82]
Wymenga 2000 716 253 228 68 15 0.79 [0.74, 0.83] 0.06 [0.03, 0.10]
Forest plot of sensitivity and specificity of tPSA testingigure 4
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a cohort study which did not exclude borderline cases of
raised PSA. This gives the appearance of poorer test accu-
racy, compared to a case-control study.
Unal 2000's isolated position in the top left on the SROC
curve produces the most significant results supporting the
use of tPSA as a diagnostic test. Its false negative rate of 0
is likely to be due to the small size of the study and its case
control design. Despite its outlying results its high meth-
odological quality warrants its inclusion.
In contrast, Aragona 2005 is the largest included study
and has the narrowest CI. Its sensitivity and specificity lies
within the main cluster of results close to the SROC curve,
adding weight to our findings.
Strengths and weaknesses of the review
A large number of abstracts were reviewed. With regards to
study design, suitable publications may have been omit-
ted due to the sole use of electronic searches, reviewer
error or limited search terms. Further detail could be
added to the searches, including the use of limited text
terms. Publication bias may occur but there is no consen-
sus on its importance [14] or how to assess the impact on
this on systematic reviews of diagnostic test accuracy [15].
As the current use of tPSA in clinical practice is debated, it
is unclear whether publication bias would exclude papers
showing a low test accuracy or high test accuracy.
The populations of our studies were limited to men
attending urology clinics because of referral due to clinical
evidence in primary or secondary care, such as an abnor-
mal DRE or raised PSA. This means that our results cannot
be applied to the screening population. In this setting
there would be a lower prevalence of prostate cancer so it
Table 3: likelihood ratios and diagnostic odds ratios with 95% confidence intervals
Study (year) Positive diagnostic likelihood ratio Negative diagnostic likelihood ratio Diagnostic odds ratio with 95% 
confidence intervals
Aragona 2005 1.081 0.549 1.970 [1.550, 2.505]
Beneduce 2007 1.382 0.408 3.387 [1.320, 8.690]
Ciatto 2004 1.188 0.405 2.930 [1.650, 5.204]
Espana 1998 0.828 3.750 0.221 [0.081, 0.603]
Fischer 2005 1.128 0.653 1.729 [0.826, 3.620]
Hofer 2000 1.274 0.327 3.899 [1.622, 9.378]
McArdle 2004 1.181 0.413 2.862 [1.211, 6.762]
Ryden 2007 1.135 0.273 4.161 [1.835, 9.435]
Unal 2000 2.900 0.000 Infinite
Wymenga 2000 0.840 3.432 0.245 [0.136, 0.440]
Forest plot of Diagnostic Odds Ratiosigure 5
Forest plot of Diagnostic Odds Ratios.
SROC Plot of tPSA testingFigure 6
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test since the specificity has been shown to be low. Also,
the populations studied were European men. A more
detailed breakdown of the race of the study populations
would have provided us with more information on
sources of heterogeneity. Overall the results can be
applied to symptomatic European men in the primary
and secondary healthcare setting.
The subgroup analyses can show valuable results, how-
ever there are some limitations. Firstly, there is overlap
between case control and cohort studies. It was sometimes
difficult to place the studies into these categories. Sec-
ondly, for our pre- and post- 1999 analysis there was only
1 study in the pre-1999 group.
Pre-1999 many assays were widely used for the detection
of total PSA, for example Tandem-E, Tandem-R, Immulite
2000, ADIVA Centaur and Roche 2. There has been signif-
icant difference in the results using the various assays [16-
18]. Also as mentioned earlier, in 1999 the World Health
Organisation established a reference standard for total
PSA measurement[5]. Since then, differences have
decreased between the results of different assay methods
[6].
Ultimately, the lack of large studies on Europeans which
were suitable for our analysis was the main limitation of
this review.
Applicability of findings to clinical practice and policy
PSA testing is clearly a vital part of the diagnostic pathway.
We have previously discussed the limitations of the study
populations. However, we can apply our results to
patients who are referred for a biopsy. This is useful for
general practitioners and urologists to reassure patients
with a raised PSA.
We have found that the PSA test had a sensitivity ranging
from 0.78 to 1.00, which means it potentially fails to diag-
nose over 20% of prostate cancers. This is important to
consider in patients with continuing symptoms or an iso-
lated, abnormal DRE. Good quality counselling and infor-
mation needs to be given to patients to ensure they
present again if symptoms persist or worsen. The DRE
needs to remain a key part in the diagnostic pathway.
PSA is known to have low specificity, however our results
show an extremely low range of 0.06 to 0.66. All but Unal
2000 showed a specificity of less than 0.40. This is in con-
trast to a moderate specificity as stated by NICE in the
most recent guidelines on referral practice for suspected
cancer in adults and children. Such a low specificity
means that in practice many patients are undergoing the
invasive procedure of biopsy who do not in fact have pros-
tate cancer. However there is currently no alternative that
has been recommended by NICE for use in clinical prac-
tice. It might be interesting to sub-analyse the data accord-
SROC curves comparing the study using the pre 1999 PSA assay and the studies using as ays from 1999 and onwardsFigure 8
SROC curves comparing the study using the pre 1999 
PSA assay and the studies using assays from 1999 and 
onwards.
Summary ROC Plot of PSA testing taking account of trial designFigure 7
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useful in the assessment of PSA as both a diagnostic test
and a screening tool.
Conclusion
Implications for practice
PSA testing still has a role to play in the diagnostic path-
way and is relatively non-invasive and inexpensive [19].
However it has a low specificity. Other tests, which could
improve this, are currently being researched but have not
been implemented into clinical practice. We recommend
that PSA testing continues to be used in clinical practice as
one of the several indicators for biopsy, but it is important
that clinicians understand the limitations of the test. It
would be interesting to assess the role of a PSA result in
GPs' decision making, for example the impact of the high
false positive and significant false negative rates.
Implications for research
As our study was unable to assess specificity and sensitiv-
ity in the screening setting it would be useful for a review
to examine this. Screening is especially relevant as pro-
grammes emerge. We would recommend that for further
research done into PSA, the STARD statements be imple-
mented to ensure standardisation and transparency. We
recommend that further research includes a sub-analysis
according to patients' symptoms.
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